New Peer‑Reviewed Study Reveals Actionable Immune–Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical Translation
Rhea-AI Summary
MediciNova (NASDAQ: MNOV) announced a peer‑reviewed study (Cancer Research, Mar 2026) identifying a MIF–CD74 vulnerability in brain metastasis and showing that the brain‑penetrant small molecule ibudilast (MN‑166) can inhibit this pathway in preclinical models.
The study reports reduced metastatic progression with MIF–CD74 inhibition, identification of secreted MIF detectable in cerebrospinal fluid as a candidate biomarker, transcriptomic signatures tied to response, and planned collaboration with CNIO to advance translational clinical research.
Positive
- Peer‑reviewed publication in Cancer Research (March 2026)
- Ibudilast (MN‑166) shown to block MIF–CD74 signaling in preclinical models
- Secreted MIF detected in cerebrospinal fluid as a candidate liquid biopsy biomarker
- Transcriptomic biomarker signatures identified to support patient stratification
- Company holds granted patents covering MN‑166 for preventing metastasis
- Planned collaboration with CNIO to pursue clinical research in brain metastases
Negative
- Efficacy reported is preclinical; no human clinical efficacy data reported
- Translational path requires clinical validation of CSF biomarker and predictive signatures
- Patients with brain metastases have historically been excluded from many trials, complicating rapid enrollment
Key Figures
Market Reality Check
Peers on Argus
MNOV was flat while peers were mixed: QNTM rose 21.92%, ABVC gained 0.93%, and ALXO and ANL fell 4.79% and 5.7%, respectively, indicating stock-specific rather than sector-driven dynamics.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 16 | Conference participation | Positive | +5.9% | ROTH conference participation and investor meetings highlighting company updates. |
| Jan 29 | ALS EAP enrollment | Positive | -1.7% | Milestone of 100 ALS patients enrolled in NIH‑funded SEANOBI EAP. |
| Jan 06 | Corporate update letter | Neutral | +0.0% | CEO New Year letter outlining 2025 progress and 2026 clinical priorities. |
| Dec 18 | Phase 2 enrollment complete | Positive | -1.4% | Completion of Phase 2 OXTOX enrollment for MN‑166 in chemotherapy neuropathy. |
| Dec 08 | ALS trial update | Neutral | -3.2% | Baseline and enrollment update from COMBAT‑ALS Phase 2b/3 trial presentation. |
Recent operational and clinical updates have often seen muted or negative price reactions, even when the news itself was constructive.
Over the last several months, MediciNova has highlighted clinical and corporate milestones centered on MN‑166 and MN‑001. Updates have included completed enrollment in a Phase 2 OXTOX study, progress in the COMBAT‑ALS Phase 2b/3 trial, and expansion of an ALS access program backed by a $22 million NIH grant. A conference appearance in March 2026 saw a positive move, while other clinically oriented announcements around late 2025 and early 2026 produced modest declines, suggesting a cautious trading pattern around pipeline news.
Market Pulse Summary
This announcement details peer‑reviewed preclinical evidence that MN‑166 (ibudilast) can modulate MIF–CD74‑driven immune–microenvironment changes in brain metastasis and identifies secreted MIF as a potential liquid biopsy biomarker. It adds a neuro‑oncology angle to MediciNova’s existing MN‑166 programs. In light of prior ALS and neuropathy studies and ongoing operating losses noted in filings, investors may watch for concrete clinical trial designs, biomarker‑guided strategies, and future regulatory interactions stemming from these findings.
Key Terms
microglia medical
liquid biopsy medical
cerebrospinal fluid medical
transcriptomic medical
biomarker medical
brain metastasis medical
AI-generated analysis. Not financial advice.
LA JOLLA, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that a study conducted by researchers at the Spanish National Cancer Research Centre (CNIO) has identified macrophage migration inhibitory factor (MIF)–mediated reprogramming of CD74‑positive microglia and macrophages as a central vulnerability in brain metastasis. The research, recently published in the peer‑reviewed journal “Cancer Research” (March 2026), demonstrates pharmacological modulation of this pathway using the brain‑penetrant small molecule ibudilast.
The work, led by Manuel Valiente PhD, head of CNIO Brain Metastasis group, and colleagues at CNIO, shows that tumor‑derived MIF alters the functional state of microglia and infiltrating macrophages in the brain, converting them from a potentially protective role into a pro‑metastatic one. In multiple experimental models and fresh patient‑derived brain metastasis samples, inhibition of the MIF–CD74 signaling axis significantly reduced metastatic progression. Importantly, the investigators also identified secreted MIF as a candidate liquid biopsy biomarker detectable in cerebrospinal fluid, supporting a translational, biomarker‑guided clinical strategy.
The study further demonstrates that ibudilast can effectively block MIF–CD74 signaling, reverse pro‑metastatic immune reprogramming, and suppress brain metastasis growth in preclinical systems. In addition, transcriptomic analyses define predictive biomarker signatures associated with treatment response, reinforcing the potential for patient stratification in future clinical studies. The findings suggest translational potential for MN-166 (ibudilast), the company’s leading product, in future therapeutic strategies for brain metastasis within neuro-oncology.
MediciNova plans to collaborate with Dr. Valiente and CNIO on future clinical research aimed at patients with solid tumors having brain metastases.
Dr. Valiente commented on the findings, “Brain metastases develop in up to
“Brain metastasis represents one of the most urgent and challenging frontiers in oncology,” said Dr. Kazuko Matsuda, Chief Medical Officer. “The publication of this work in Cancer Research provides strong mechanistic and translational rationale to pursue biomarker‑driven clinical strategies. We hold granted patents covering MN‑166 for preventing and minimizing cancer metastasis across multiple solid tumor types, including pancreatic, lung, breast, colorectal and ovarian cancers, as well as melanoma. Our focus is now on advancing future clinical investigations and responsibly translating these insights into studies designed for patients with brain metastases.”
The full study, “MIF‑Induced CD74+ Microglia and Macrophages Promote Progression of Brain Metastasis and Are Clinically Relevant Across Central Nervous System Disorders,” is available online in Cancer Research. (https://doi.org/10.1158/0008-5472.CAN-25-4018 )
About MediciNova
MediciNova, Inc. is a clinical-stage biopharmaceutical company developing a broad late-stage pipeline of novel small molecule therapies for inflammatory, fibrotic, and neurodegenerative diseases. Based on two compounds, MN-166 (ibudilast) and MN-001 (tipelukast), with multiple mechanisms of action and strong safety profiles, MediciNova has numerous programs in clinical development. MediciNova’s lead asset, MN-166 (ibudilast), is currently in Phase 3 for amyotrophic lateral sclerosis (ALS) and degenerative cervical myelopathy (DCM) and is Phase 3-ready for progressive multiple sclerosis (MS). MN-166 (ibudilast) is also being evaluated in Phase 2 trials in Long COVID and substance dependence. MN-001 (tipelukast) was evaluated in a Phase 2 trial in idiopathic pulmonary fibrosis (IPF) and a second Phase 2 trial in non-alcoholic fatty liver disease (NAFLD) is ongoing. MediciNova has a strong track record of securing investigator-sponsored clinical trials funded through government grants.
Forward-Looking Statements
Statements in this press release that are not historical in nature constitute forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements regarding the future development and efficacy of MN-166 and MN-001. These forward-looking statements may be preceded by, followed by, or otherwise include the words "believes," "expects," "anticipates," "intends," "estimates," "projects," "can," "could," "may," "will," "would," “considering,” “planning” or similar expressions. These forward-looking statements involve a number of risks and uncertainties that may cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Factors that may cause actual results or events to differ materially from those expressed or implied by these forward-looking statements include, but are not limited to, risks of obtaining future partner or grant funding for development of MN-166 and MN-001, and risks of raising sufficient capital when needed to fund MediciNova's operations and contribution to clinical development, risks and uncertainties inherent in clinical trials, including the potential cost, expected timing and risks associated with clinical trials designed to meet FDA guidance and the viability of further development considering these factors, product development and commercialization risks, the uncertainty of whether the results of clinical trials will be predictive of results in later stages of product development, the risk of delays or failure to obtain or maintain regulatory approval, risks associated with the reliance on third parties to sponsor and fund clinical trials, risks regarding intellectual property rights in product candidates and the ability to defend and enforce such intellectual property rights, the risk of failure of the third parties upon whom MediciNova relies to conduct its clinical trials and manufacture its product candidates to perform as expected, the risk of increased cost and delays due to delays in the commencement, enrollment, completion or analysis of clinical trials or significant issues regarding the adequacy of clinical trial designs or the execution of clinical trials, and the timing of expected filings with the regulatory authorities, MediciNova's collaborations with third parties, the availability of funds to complete product development plans and MediciNova's ability to obtain third party funding for programs and raise sufficient capital when needed, and the other risks and uncertainties described in MediciNova's filings with the Securities and Exchange Commission, including its annual report on Form 10-K for the year ended December 31, 2025 and its subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Undue reliance should not be placed on these forward-looking statements, which speak only as of the date hereof. MediciNova disclaims any intent or obligation to revise or update these forward-looking statements.
INVESTOR CONTACT:
David H. Crean, Ph.D.
Chief Business Officer
MediciNova, Inc
info@medicinova.com
